News | Artificial Intelligence | November 18, 2019

Visage to Spotlight the Visage 7 Enterprise Imaging Platform at RSNA

The company will demonstrate the imaging platform in a new 3,200 sq. ft. booth in the North Hall, McCormick Place

November 18, 2019 — Visage Imaging, Inc. (Visage), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced Visage will be exhibiting under the theme of "Platform for the Future—Powered by Speed," highlighted by the demonstration of the Visage 7 Enterprise Imaging Platform, at the Radiological Society of North America (RSNA) 2019 annual meeting (Visage Booth 7524, McCormick Place-North Hall), Dec. 1-5, in Chicago, Ill.

Visage 7 has advanced Enterprise Imaging based on the proven ability to replace legacy PACS for imaging organizations of all sizes and local, regional or national scale. Five of the 2019-2020 top 20 ranked U.S. hospitals have chosen Visage 7, more than any other PACS.

One of the key drivers of this change has been the relentless growth of datasets produced by modern imaging modalities such as large cross-sectional (CT/MR) and digital breast tomosynthesis (DBT), and now high-resolution DBT ("High-res DBT"). These datasets, which are often combined with numerous prior imaging studies, are creating major bottlenecks for legacy 'compress and send' technology.

"The challenges of data explosion are placing significant stress on healthcare institutions, particularly when it comes to imaging," explained Malte Westerhoff, PhD, Visage Imaging Co-Founder and Chief Technology Officer. Westerhoff continued, "While we'll continue to successfully scale the underlying platform to cope with the exponentially growing compute and data handling requirements, that is only one part of the solution. Continuous innovation in how the system can aid and guide users in understanding data quickly, efficiently and reliably is also needed to allow users to benefit from the additional resolution and information contained in these growing datasets, instead of slowing them down. This involves user interface enhancements, AI-based data analysis and seamless information exchange with other IT systems in the modern enterprise."

At RSNA 2019, the following highlights will be demonstrated and discussed:

  • High-res DBT. Visage 7 supports the diagnostic interpretation of high-res DBT, delivered on-demand and in real-time, by ultrafast server-side processing.
  • Ophthalmology. With One Viewer, Visage 7 now supports even more clinical data, including PDF documents and ophthalmology images, enabling the elimination of legacy ophthalmology PACS.
  • Go-live flexibility. A Visage exclusive, Visage 7 enables customers to go-live enterprise-wide, assembling the imaging patient jacket on-the-fly with all priors, even if customer data migration is incomplete, from one or multiple PACS.
  • Breast MR multiparametric color maps. A preview of capabilities projected for Visage 7.1.15 will be demonstrated, including Breast MR multiparametric color maps for diffusion-weighted imaging as a works-in-progress (WIP). Visage 7 will be demonstrated with native, specialized toolsets for calculation and color mapped visualization of kinetic information in Breast MR images with elastic registration. 
  • Visage AI Accelerator. Visage will introduce the Visage AI Accelerator, an end-to-end AI solution that bridges both research and diagnostic imaging with the same, unified platform (WIP).
  • Visage 7 in the cloud. Highly optimized for cloud deployment, Visage 7 is the industry's first cloud-engineered server-side platform for complete PACS operations. Visage 7 in the cloud can offer the same ultrafast speed and functionality of on-premise implementations, but with the added security and scale of the cloud.
  • Visage 7 Workflow. Visage 7 now offers integrated, native workflow enabling customers to unify and manage reading worklists. Customers now have the choice of driving their reading workflow from independent workflow platforms, EHR-driven workflow, or natively with Visage 7.

Visage will be exhibiting in a new 3,200 sq. ft. booth in the North Hall, McCormick Place. To schedule a priority demonstration of Visage 7 or to meet with Visage at RSNA 2019, please visit this link for additional details.

For more information: www.visageimaging.com

Related Content

Image courtesy of GE Healthcare

Feature | Mobile C-Arms | July 08, 2020 | By Melinda Taschetta-Millane
Moblie C-arms have seen several advances over the past de
At the American Association of Physicists in Medicine (AAPM) 2019 meeting, new artificial intelligence (AI) software to assist with radiotherapy treatment planning systems was highlighted. The goal of the AI-based systems is to save staff time, while still allowing clinicians to do the final patient review. 
Feature | Treatment Planning | July 08, 2020 | By Melinda Taschetta-Millane
At the American Association of Physicists in Medicine (AAPM) 201
Hologic, Inc. announced he U.S. launch of the SuperSonic MACH 40 ultrasound system, expanding the company’s suite of ultrasound technologies with its first premium, cart-based system.
News | Breast Imaging | July 08, 2020
July 8, 2020 — Hologic, Inc. announced he U.S.
Several drivers will contribute to the growth of the teleradiology market in terms of penetration, revenue and read volumes over the next five years

Getty Images

Feature | Teleradiology | July 08, 2020 | By Arun Gill
Last year was a record year for the global...
A 3-D ultrasound system provides an effective, noninvasive way to estimate blood flow that retains its accuracy across different equipment, operators and facilities, according to a study published in the journal Radiology.

Volume flow as a function of color flow gain (at a single testing site). For each row the color flow c-plane and the computed volume flow are shown as a function of color flow gain. The c-plane is shown for four representative gain levels, whereas the computed volume flow is shown for 12–17 steps across the available gain settings. Flow was computed with (solid circles on the graphs) and without (hollow circles on the graphs) partial volume correction. Partial volume correction accounts for pixels that are only partially inside the lumen. Therefore, high gain (ie, blooming) does not result in overestimation of flow. Systems 1 and 2 converge to true flow after the lumen is filled with color pixel. System 3 is nearly constant regarding gain and underestimates the flow by approximately 17%. Shown are mean flow estimated from 20 volumes, and the error bars show standard deviation. Image courtesy of the journal Radiology

News | Ultrasound Imaging | July 01, 2020
July 1, 2020 — A 3-D ultrasound
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...